ʻO Vericiguat kahipyrazolopyridineʻo ia5-fluoro-1H-pyrazolo[3,4-b]pyridinekahi i hoʻololi ʻia ai ka amino hydrogen ma ke kūlana 1 e kahi hui 2-fluorobenzyl a me kahydrogenma ke kūlana 3 ua hoʻololi ʻia e kahi hui 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl. He mea hoʻoheheʻeguanylatecyclase stimulator i hoʻohana ʻia no ka mālama ʻana i ka maʻi ʻole o ka naʻau. He kuleana kona ma ke ʻano he mea hoʻoheheʻeguanylatecyclase activator, he lāʻau vasodilator a he lāʻau antihypertensive. Heaminopyrimidine, apyrazolopyridine, he ester carbamate a me ka hui organofluorine.

Ke hoʻokolokolo ʻia nei ʻo Vericiguat ma ka hoʻokolohua lapaʻau NCT02861534 (He Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)).

ʻO Vericiguat kahi mea hoʻoheheʻeGuanylateMea hoʻoikaika kino. ʻO ka hana o ka vericiguat e like me aGuanylateMea hoʻoikaika kino.

He lāʻau lapaʻau ʻo Vericiguat i hoʻohana ʻia no ka mālama ʻana a me ka mālama ʻana i ka pau ʻole o ka naʻau me ka haʻihaʻi ejection liʻiliʻi (HFrEF). He mea maikaʻi ia no ka hōʻino ʻole ʻana o ka naʻau, ka puʻuwai decompensated hou. ʻAʻole hoʻolōʻihi ʻo Vericiguat i ke ola akā pale i ka rehospitalization. Hōʻike kēia haʻawina i nā hōʻailona, ​​​​mekini o ka hana, dosis, a me ke ʻano o ka hoʻokele ʻana e ka hui interprofessional, nā hopena ʻino, contraindications, a me kekahi mau hoʻāʻo e kākoʻo i nā hōʻike o ka pono o ka lāʻau i ka HFrEF.